approved by FDA for use as a smoking cessation aid.

[3Smokr]

Hi all,

http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm173146.htm

One high-nicotine cartridge delivered twice as much nicotine to users when the vapor from that electronic cigarette brand was inhaled than was delivered by a sample of the nicotine inhalation product (used as a control) approved by FDA for use as a smoking cessation aid.

some one translate this to simple English I couldnt understand it

 

[mi528hz]

They are saying that their test ecig gave twice as much nic as their control ecig. They are missing info here, I belive. What was there test ecig? HOW MUCH NIC WAS IN IT? I figured each seperate vape inhale would have different amounts of nic.

 

[CES]

The FDA study that was referenced in you link has been misrepresented. Here's a link http://www.casaa.org/files/Exponent%20Response-to-the-FDA-Summary.pdf to a document addressing many of the issues with the FDA study. From the conclusions:

The detection of trace and non-measurable levels of TSNAs and tobacco-associated impurities in the liquid, rather than the vapor phase of NJOY’s products, at levels that are many orders of magnitude below conventional cigarettes, and at or below FDA-approved nicotine containing products, should be considered as indicators of the regulatory acceptability of the NJOY products rather than reason for concern. When considering the relative potential health risks posed by these trace levels, it is worth noting that the approved NRTs, which have been shown to contain these substances, were not judged to contain levels sufficient to warrant toxicity information or reference to these substances in their own product literature.

you can find links to lab reports, published studies and a lot of other helpful information at CASAA.org

 

[PoliticallyIncorrect]

This is so, so frustrating.

On one hand, you have a misreprersented (i.e., butchered) summary of a study conducted by the FDA--a virtual proxy for the pharmeceutical makers of smoking cessation aids, high-profit products with a demonstrated record of mediocre short-term effectiveness and a woefully high rate of recidivism going forward.

On the other, a paid response prepared by a Ph.D--who will immediately be labeled a .....--on the behest of one Jack Leadbeater, President and CEO of NJOY.